S&P 500   4,252.10 (+0.54%)
DOW   33,090.62 (+0.27%)
QQQ   357.92 (+0.85%)
AAPL   172.71 (+0.18%)
MSFT   318.29 (+1.56%)
META   304.51 (+1.19%)
GOOGL   134.94 (+1.90%)
AMZN   125.98 (+1.01%)
TSLA   255.88 (+3.79%)
NVDA   441.09 (+1.36%)
NIO   8.73 (+1.39%)
BABA   84.13 (-0.48%)
AMD   102.58 (+2.50%)
T   14.51 (-1.83%)
F   12.02 (-0.41%)
MU   67.86 (+0.04%)
CGC   0.74 (+7.95%)
GE   108.25 (+0.45%)
DIS   79.07 (-0.59%)
AMC   8.00 (+1.91%)
PFE   33.59 (-0.91%)
PYPL   58.06 (+1.33%)
NFLX   378.52 (+0.47%)
S&P 500   4,252.10 (+0.54%)
DOW   33,090.62 (+0.27%)
QQQ   357.92 (+0.85%)
AAPL   172.71 (+0.18%)
MSFT   318.29 (+1.56%)
META   304.51 (+1.19%)
GOOGL   134.94 (+1.90%)
AMZN   125.98 (+1.01%)
TSLA   255.88 (+3.79%)
NVDA   441.09 (+1.36%)
NIO   8.73 (+1.39%)
BABA   84.13 (-0.48%)
AMD   102.58 (+2.50%)
T   14.51 (-1.83%)
F   12.02 (-0.41%)
MU   67.86 (+0.04%)
CGC   0.74 (+7.95%)
GE   108.25 (+0.45%)
DIS   79.07 (-0.59%)
AMC   8.00 (+1.91%)
PFE   33.59 (-0.91%)
PYPL   58.06 (+1.33%)
NFLX   378.52 (+0.47%)
S&P 500   4,252.10 (+0.54%)
DOW   33,090.62 (+0.27%)
QQQ   357.92 (+0.85%)
AAPL   172.71 (+0.18%)
MSFT   318.29 (+1.56%)
META   304.51 (+1.19%)
GOOGL   134.94 (+1.90%)
AMZN   125.98 (+1.01%)
TSLA   255.88 (+3.79%)
NVDA   441.09 (+1.36%)
NIO   8.73 (+1.39%)
BABA   84.13 (-0.48%)
AMD   102.58 (+2.50%)
T   14.51 (-1.83%)
F   12.02 (-0.41%)
MU   67.86 (+0.04%)
CGC   0.74 (+7.95%)
GE   108.25 (+0.45%)
DIS   79.07 (-0.59%)
AMC   8.00 (+1.91%)
PFE   33.59 (-0.91%)
PYPL   58.06 (+1.33%)
NFLX   378.52 (+0.47%)
S&P 500   4,252.10 (+0.54%)
DOW   33,090.62 (+0.27%)
QQQ   357.92 (+0.85%)
AAPL   172.71 (+0.18%)
MSFT   318.29 (+1.56%)
META   304.51 (+1.19%)
GOOGL   134.94 (+1.90%)
AMZN   125.98 (+1.01%)
TSLA   255.88 (+3.79%)
NVDA   441.09 (+1.36%)
NIO   8.73 (+1.39%)
BABA   84.13 (-0.48%)
AMD   102.58 (+2.50%)
T   14.51 (-1.83%)
F   12.02 (-0.41%)
MU   67.86 (+0.04%)
CGC   0.74 (+7.95%)
GE   108.25 (+0.45%)
DIS   79.07 (-0.59%)
AMC   8.00 (+1.91%)
PFE   33.59 (-0.91%)
PYPL   58.06 (+1.33%)
NFLX   378.52 (+0.47%)
NYSE:ENFN

Enfusion (ENFN) Stock Forecast, Price & News

$8.85
+0.06 (+0.68%)
(As of 11:45 AM ET)
Compare
Today's Range
$8.71
$8.89
50-Day Range
$7.83
$10.85
52-Week Range
$7.37
$14.61
Volume
35,872 shs
Average Volume
419,424 shs
Market Capitalization
$1.09 billion
P/E Ratio
110.64
Dividend Yield
N/A
Price Target
$11.00

Enfusion MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
24.3% Upside
$11.00 Price Target
Short Interest
Bearish
4.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Enfusion in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$10.84 M Sold Last Quarter
Proj. Earnings Growth
90.00%
From $0.10 to $0.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Computer And Technology Sector

155th out of 595 stocks

Prepackaged Software Industry

43rd out of 197 stocks


ENFN stock logo

About Enfusion (NYSE:ENFN) Stock

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.

ENFN Price History

ENFN Stock News Headlines

Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Is Enfusion, Inc. (NYSE:ENFN) Trading At A 30% Discount?
Enfusion (NYSE: ENFN)
Enfusion Inc.
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Enfusion Inc. Class A
Enfusion (ENFN) Receives a Buy from Stifel Nicolaus
J.P. Morgan Keeps Their Hold Rating on Enfusion (ENFN)
Enfusion (ENFN) Gets a Hold from Goldman Sachs
Why Enfusion (ENFN) Stock Is Exploding Higher
Enfusion: Multiple Catalysts
See More Headlines
Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

ENFN Company Calendar

Last Earnings
8/08/2023
Today
10/04/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
1,006
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+24.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-7,650,000.00
Pretax Margin
6.35%

Debt

Sales & Book Value

Annual Sales
$150.35 million
Book Value
$0.91 per share

Miscellaneous

Free Float
75,069,000
Market Cap
$1.09 billion
Optionable
Not Optionable
Beta
0.79
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Oleg Movchan (Age 48)
    CEO & Director
    Comp: $876.34k
  • Mr. Bradley Herring (Age 52)
    Chief Financial Officer
    Comp: $267.05k
  • Ms. Bronwen Bastone (Age 50)
    Chief People Officer
    Comp: $566.25k
  • Mr. Stephen Malherbe
    Managing Partner
  • Mr. Michael Berry
    Chief Operating Officer
  • Mr. Daniel Groman (Age 34)
    Chief Technology Officer
  • Mr. Ignatius Tochukwu Njoku
    Head of Investor Relations
  • Matt Campobasso
    Gen. Counsel
  • Mr. Dan Jacobs
    Global Head of Sales
  • Caroline Ma
    Head of Corp. Devel.













ENFN Stock - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares.
View ENFN analyst ratings
or view top-rated stocks.

What is Enfusion's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year price objectives for Enfusion's shares. Their ENFN share price forecasts range from $9.00 to $14.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for ENFN
or view top-rated stocks among Wall Street analysts.

How have ENFN shares performed in 2023?

Enfusion's stock was trading at $9.67 at the start of the year. Since then, ENFN shares have decreased by 8.6% and is now trading at $8.84.
View the best growth stocks for 2023 here
.

Are investors shorting Enfusion?

Enfusion saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,750,000 shares, an increase of 36.7% from the August 31st total of 1,280,000 shares. Based on an average daily volume of 421,100 shares, the days-to-cover ratio is currently 4.2 days. Currently, 4.1% of the shares of the stock are sold short.
View Enfusion's Short Interest
.

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ENFN earnings forecast
.

How were Enfusion's earnings last quarter?

Enfusion, Inc. (NYSE:ENFN) released its quarterly earnings data on Tuesday, August, 8th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The company earned $42.72 million during the quarter, compared to the consensus estimate of $44.58 million. Enfusion had a net margin of 3.61% and a trailing twelve-month return on equity of 8.10%.

What guidance has Enfusion issued on next quarter's earnings?

Enfusion issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $170.00 million-$175.00 million, compared to the consensus revenue estimate of $186.50 million.

When did Enfusion IPO?

(ENFN) raised $300 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

What is Enfusion's stock symbol?

Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN."

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enfusion's stock price today?

One share of ENFN stock can currently be purchased for approximately $8.84.

How much money does Enfusion make?

Enfusion (NYSE:ENFN) has a market capitalization of $1.09 billion and generates $150.35 million in revenue each year. The company earns $-7,650,000.00 in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does Enfusion have?

The company employs 1,006 workers across the globe.

How can I contact Enfusion?

The official website for the company is www.enfusion.com. The company can be reached via phone at 312-253-9800 or via email at brian.murphy@icrinc.com.

This page (NYSE:ENFN) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -